4572 Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Carna Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥310.00 |
| 52 Week High | JP¥876.00 |
| 52 Week Low | JP¥285.00 |
| Beta | 0.62 |
| 11 Month Change | -10.40% |
| 3 Month Change | -9.62% |
| 1 Year Change | -61.87% |
| 33 Year Change | -67.71% |
| 5 Year Change | -84.60% |
| Change since IPO | -70.19% |
Recent News & Updates
Recent updates
Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Aug 06
What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You
Apr 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26
Shareholder Returns
| 4572 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -1.0% | 3.0% | 0.3% |
| 1Y | -61.9% | -26.6% | 15.7% |
Return vs Industry: 4572 underperformed the JP Life Sciences industry which returned -26.6% over the past year.
Return vs Market: 4572 underperformed the JP Market which returned 15.7% over the past year.
Price Volatility
| 4572 volatility | |
|---|---|
| 4572 Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4572's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4572's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 67 | Kohichiro Yoshino | www.carnabio.com |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services.
Carna Biosciences, Inc. Fundamentals Summary
| 4572 fundamental statistics | |
|---|---|
| Market cap | JP¥6.09b |
| Earnings (TTM) | -JP¥1.36b |
| Revenue (TTM) | JP¥1.44b |
4.1x
P/S Ratio-4.4x
P/E RatioIs 4572 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4572 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.44b |
| Cost of Revenue | JP¥174.00m |
| Gross Profit | JP¥1.27b |
| Other Expenses | JP¥2.63b |
| Earnings | -JP¥1.36b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -71.26 |
| Gross Margin | 87.92% |
| Net Profit Margin | -94.51% |
| Debt/Equity Ratio | 2.7% |
How did 4572 perform over the long term?
See historical performance and comparison